In partnership with three Thai state-owned organisations, CSIRO’s Biotherapeutics team is improving Thailand’s capacity to manufacture essential drugs and improve local and equitable access to medicines. Project activities include trainings at CSIRO’s state-of-the-art facilities in Victoria, Australia where project partners are supported to perform end-to-end process development work on drugs selected by the Thai partners based on national priorities.

CSIRO’s Biotherapeutics team has partnered with the Malaysia Genome and Vaccine Institute (MGVI-NIBM) to build MGVI’s capability to manufacture vaccines, including a Leptospirosis vaccine.

CSIRO support is provided through in-person train‑the‑trainer programs – covering technology readiness and manufacturability assessment – and quality assessments and backstopping observation of MGVI staff.

Australia's Department of Foreign Affairs and Trade is partnering with the Therapeutic Goods Administration (TGA) to co-deliver the Indo-Pacific Regulatory Strengthening Program (RSP). This program extends the previous TGA-led RSP and covers 22 countries across our region.

Australia is supporting the Global Alliance for TB Drug Development (TB Alliance) to advance TB treatments through innovative research and capacity building. TB Alliance is improving outcomes for all TB patients and communities through trialling and developing shorter, simplified and more affordable treatment regimes. To ensure faster uptake and access to new life-saving TB treatments, TB Alliance has created a Manila-based peer-to-peer knowledge hub for countries to learn from other national TB programs for implementation of new guidelines and to support clinical training.

Australia’s investment in PATH is helping to advance diagnostic tools for malaria and neglected tropical diseases through research, development, and clinical evaluation. This investment represents a product development partnership between PATH, Burnet Institute and WEHI. This work supports Australian manufacturers to generate tools needed for the availability of novel malaria rapid diagnostic tests, and assays for malaria relapse risk assessment and treatment.

Australia’s partnership with Medicine for Malaria Venture (MMV) is supporting the research and development of malaria treatment and prevention products. This includes new chemical entities for malaria case management and prevention; new intramuscular chemoprevention candidates to provide coverage longer than three months; and the first-ever malaria relapse prevention candidate free of G6PD (an enzyme that helps red blood cells work correctly) -deficiency liabilities.

Australia is supporting Medicines Development for Global Health (MDGH) to advance the development and delivery of two medicines, moxidectin and dovramilast, for the treatment of some of the world’s most challenging, disfiguring and stigmatising infectious diseases. Scabies, lymphatic filariasis and leprosy type 2 reaction negatively impact the lives of hundreds of millions of people globally and have some of the highest reported prevalence rates in the Indo-Pacific.

IVCC develops innovative vector control tools to guard against malaria and dengue-carrying mosquitoes. With DFAT support, IVCC will expand a vector control toolbox tailored to Indo-Pacific contexts, better equipping countries to prevent and manage outbreaks and ultimately eliminate Vector Borne Diseases.
Activities include:
 

Through the mSupply open project, open source software will be made available for installation that will facilitate medical product registration and stock management of medical products across health system levels.

Through a scholarship program, national regulatory authority staff will complete postgraduate level courses from the Graduate Certificate in Health Products Regulation program at Duke-National University of Singapore.